EASL 2013: 12 Weeks of Telaprevir Triple Therapy Adequate for Some Hep C Patients
- Details
- Category: HCV Treatment
- Published on Thursday, 13 June 2013 00:00
- Written by Liz Highleyman
Nearly 90% of genotype 1 chronic hepatitis C patients with favorable response factors including the IL28B CC gene variant achieved a cure with just 12 weeks of telaprevir (Incicek or Incivo) plus pegylated interferon/ribavirin, rising to 97% for those treated for 24 weeks, researchers reported at the recent EASL International Liver Congress (EASL 2013) in Amsterdam.
Web Design and Development by